Takeda Pharmaceutical (TAK) News Today $15.10 +0.10 (+0.63%) As of 10:28 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Takeda Pharmaceutical (NYSE:TAK) Sets New 12-Month High - Time to Buy?Takeda Pharmaceutical (NYSE:TAK) Sets New 12-Month High - Should You Buy?March 25 at 9:48 AM | marketbeat.comSummit Global Investments Has $9.66 Million Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)Summit Global Investments lifted its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 75.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 729,200 shares of the comMarch 23 at 5:49 AM | marketbeat.com69,083 Shares in Takeda Pharmaceutical Company Limited (NYSE:TAK) Bought by Boston PartnersBoston Partners bought a new position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 69,083 shares of the company's stoMarch 23 at 4:24 AM | marketbeat.comNatixis Advisors LLC Acquires 21,539 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)Natixis Advisors LLC lifted its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 4.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 478,579 shares of theMarch 23 at 3:54 AM | marketbeat.comSignaturefd LLC Raises Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)Signaturefd LLC boosted its position in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 43.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 65,097 shares of the cMarch 21, 2025 | marketbeat.comTakeda Pharmaceutical (NYSE:TAK) Hits New 12-Month High - What's Next?Takeda Pharmaceutical (NYSE:TAK) Sets New 12-Month High - Time to Buy?March 18, 2025 | marketbeat.comTakeda Pharmaceutical Company Limited (NYSE:TAK) Position Lowered by Brandes Investment Partners LPBrandes Investment Partners LP decreased its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 5.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,039,585 shares of the company's stock after selling 192,019 sharMarch 16, 2025 | marketbeat.comJapan union group says gained hefty average 2025 pay hike, albeit less than last yearMarch 14, 2025 | msn.comMajor Japan union group says agreements struck for average 5.37% pay hikeMarch 13, 2025 | msn.comTakeda: Buy Into Future Drug Pipeline Potential, Despite Recent Profit HeadwindsMarch 13, 2025 | seekingalpha.comCallan Family Office LLC Buys Shares of 19,924 Takeda Pharmaceutical Company Limited (NYSE:TAK)Callan Family Office LLC bought a new stake in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 19,924 shares of the company's stock, vMarch 11, 2025 | marketbeat.comMass. man gets prison time for defrauding Takeda Pharmaceutical Co. of $2.3MMarch 11, 2025 | msn.comNaviter Wealth LLC Has $228,000 Stock Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)Naviter Wealth LLC cut its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 79.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 17,227 shares of the company's stock after selling 68,248 shares during the period. NavMarch 10, 2025 | marketbeat.comUS Bancorp DE Has $1.65 Million Stock Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)US Bancorp DE increased its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 21.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 124,332 shares of the company's sMarch 9, 2025 | marketbeat.comFisher Asset Management LLC Buys New Shares in Takeda Pharmaceutical Company Limited (NYSE:TAK)Fisher Asset Management LLC bought a new stake in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 41,334 shares of the company's stock, valued atMarch 7, 2025 | marketbeat.comTakeda Pharmaceutical (NYSE:TAK) Reaches New 1-Year High - What's Next?Takeda Pharmaceutical (NYSE:TAK) Reaches New 1-Year High - Time to Buy?March 6, 2025 | marketbeat.comMolecular Glues Competitive Landscape 2025: Exploring 65+ Drugs and 50+ Biotech Players in the Molecular Glue SpaceMarch 6, 2025 | finance.yahoo.comOppenheimer Asset Management Inc. Reduces Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)Oppenheimer Asset Management Inc. decreased its position in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 70.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 59,051 shares of the compaMarch 5, 2025 | marketbeat.comTakeda Pharmaceutical (NYSE:TAK) Trading Up 3.1% - Should You Buy?Takeda Pharmaceutical (NYSE:TAK) Stock Price Up 3.1% - Still a Buy?March 4, 2025 | marketbeat.comSanctuary Advisors LLC Sells 40,570 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)Sanctuary Advisors LLC lessened its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 57.9% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 29,451 shares of the company's stock after sMarch 4, 2025 | marketbeat.comProtagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia VeraMarch 3, 2025 | businesswire.comMETiS Pharmaceuticals Appoints Mark Herbert as Chief Business OfficerMarch 3, 2025 | finance.yahoo.comTakeda Pharmaceutical Company Limited (NYSE:TAK) Shares Acquired by QRG Capital Management Inc.QRG Capital Management Inc. lifted its position in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 16.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 329,644 shares of the company's stock aMarch 1, 2025 | marketbeat.comIs Takeda Pharmaceutical Company Limited (TAK) the Best Low Price Pharma Stock to Invest In Right Now?February 27, 2025 | msn.comTakeda announces EMA approval for Takhzyro two mL pre-filled pen optionFebruary 24, 2025 | markets.businessinsider.comThe European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)February 24, 2025 | prnewswire.comTrump Set To Break WTO Rules With Potential Pharma TariffsFebruary 20, 2025 | seekingalpha.comPetri Dish: One Boston biotech shuts down, another bags $90MFebruary 20, 2025 | bizjournals.comHow the owner of Rebelle in Kendall Square traded in beakers for bagelsFebruary 19, 2025 | bizjournals.comIs Takeda Pharmaceutical Company Limited (TAK) the Best Japanese Stock to Buy in 2025?February 15, 2025 | insidermonkey.comVan ECK Associates Corp Grows Stock Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)Van ECK Associates Corp grew its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 1.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,210,428 shares of the companyFebruary 15, 2025 | marketbeat.comStrong Q3, Improved Guidance Are Signs Takeda Pharmaceutical May Be UndervaluedJanuary 31, 2025 | seekingalpha.comTakeda announces appointment of Julie Kim as CEOJanuary 31, 2025 | msn.comTakeda Pharmaceutical Company Limited (NYSE:TAK) Sees Significant Decrease in Short InterestTakeda Pharmaceutical Company Limited (NYSE:TAK - Get Free Report) saw a significant drop in short interest in the month of January. As of January 15th, there was short interest totalling 3,710,000 shares, a drop of 24.4% from the December 31st total of 4,910,000 shares. Based on an average daily volume of 1,710,000 shares, the short-interest ratio is presently 2.2 days.January 31, 2025 | marketbeat.comTakeda Pharmaceutical Company Limited (TAK) Q3 2025 Earnings Call TranscriptJanuary 30, 2025 | seekingalpha.comTakeda Pharmaceutical (NYSE:TAK) Announces Earnings ResultsTakeda Pharmaceutical (NYSE:TAK - Get Free Report) posted its quarterly earnings data on Thursday. The company reported $0.42 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 6.49% and a return on equity of 10.00%.January 30, 2025 | marketbeat.comTakeda Pharmaceutical (NYSE:TAK) Updates FY 2024 Earnings GuidanceTakeda Pharmaceutical (NYSE:TAK) updated its FY 2024 earnings guidance. The company provided EPS guidance of 3.330-3.330 for the period.January 30, 2025 | marketbeat.comTakeda Pharmaceutical (TAK) Projected to Post Quarterly Earnings on ThursdayTakeda Pharmaceutical (NYSE:TAK) will be releasing earnings before the market opens on Thursday, February 6, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=656816)January 30, 2025 | marketbeat.comJulie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026January 30, 2025 | businesswire.comJapan's Takeda says Q3 profit slid 38%, trailing analyst estimatesJanuary 30, 2025 | reuters.comTakeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin GrowthJanuary 30, 2025 | businesswire.comNeurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653)January 27, 2025 | prnewswire.comNovo Nordisk (NVO) Gets a Buy from TD CowenJanuary 24, 2025 | markets.businessinsider.comTakeda-backed Ascentage Pharma aims to raise $126 million in US IPOJanuary 24, 2025 | msn.comCrossmark Global Holdings Inc. Purchases 155,795 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)Crossmark Global Holdings Inc. lifted its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 284.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 210,4January 23, 2025 | marketbeat.comTakeda-backed Ascentage Pharma targets $1.75 billion valuation in US IPOJanuary 21, 2025 | reuters.comLegacy Wealth Asset Management LLC Sells 20,779 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)Legacy Wealth Asset Management LLC lessened its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 12.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 140,837 sharJanuary 17, 2025 | marketbeat.comTakeda Pharmaceutical Company Limited (NYSE:TAK) Shares Sold by Clean Yield GroupClean Yield Group trimmed its position in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 11.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 360,091 shares of the company's stock after sellinJanuary 13, 2025 | marketbeat.comBoston office market starts 2025 with record-high vacancy rateJanuary 9, 2025 | bizjournals.comTakeda Pharmaceutical (NYSE:TAK) Sees Unusually-High Trading Volume - Here's WhyTakeda Pharmaceutical (NYSE:TAK) Sees Unusually-High Trading Volume - Here's What HappenedJanuary 8, 2025 | marketbeat.com Remove Ads Get Takeda Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for TAK and its competitors with MarketBeat's FREE daily newsletter. Email Address TAK Media Mentions By Week TAK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TAK News Sentiment▼0.740.63▲Average Medical News Sentiment TAK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TAK Articles This Week▼54▲TAK Articles Average Week Remove Ads Get Takeda Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for TAK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SNY News Today GSK News Today ARGX News Today ONC News Today BNTX News Today TEVA News Today SMMT News Today ITCI News Today MRNA News Today GMAB News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:TAK) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Takeda Pharmaceutical Company Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Takeda Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.